Investigating how PAI-1 affects blood vessel function and Alzheimer's disease development
The Role of PAI-1 in Cerebral Microvascular Dysfunction and the Development of Alzheimer’s Disease Neuropathology
This study is looking at how a protein called PAI-1 might affect tiny blood vessels in the brain and its connection to Alzheimer's disease, especially how heart health can influence this, with the hope of finding new ways to diagnose or treat the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10864941 on NIH RePORTER |
What this research studies
This research explores the role of plasminogen activator inhibitor 1 (PAI-1) in the dysfunction of cerebral microvessels and its potential link to Alzheimer's disease (AD). By examining how cardiovascular disease risk factors influence PAI-1 levels and contribute to cognitive decline, the study aims to uncover new pathways that may lead to AD. The approach includes analyzing biological samples and using animal models to understand the mechanisms involved. Patients may benefit from insights that could lead to new diagnostic tools or treatments targeting PAI-1.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for Alzheimer's disease, particularly those with cardiovascular risk factors.
Not a fit: Patients with established Alzheimer's disease who are not at risk due to cardiovascular factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for diagnosing or treating Alzheimer's disease by targeting PAI-1.
How similar studies have performed: Previous research has shown promising results linking vascular factors to Alzheimer's disease, suggesting that this approach may yield valuable insights.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Lawrence, Daniel a — University of Michigan at Ann Arbor
- Study coordinator: Lawrence, Daniel a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.